A Study of LY3502970 in Healthy Participants
Phase 1
Completed
NCT03929744
| Condition | Healthy |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 133 participants |
|---|
| Interventions | LY3502970, Atorvastatin, Simvastatin, Midazolam |
|---|
| Start date | Jun 12, 2019 |
|---|
| Completion date | Nov 2, 2020 |
|---|
| Results posted | Jul 10, 2026 |
|---|
Summary
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Baseline through Follow-up (up to Day 42) · Participants
| Part A Placebo | 0 Participants |
|---|
| Part A 0.3 mg LY3502970 | 0 Participants |
|---|
| Part A 1 mg LY3502970 | 0 Participants |
|---|
| Part A 3 mg LY3502970 | 0 Participants |
|---|
| Part A 6 mg LY3502970 | 0 Participants |
|---|
| Part B Placebo | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.